(Q35020743)

5 August 2017

1 reference

title

Inflammatory bowel disease: new insights into pathogenesis and treatment (English)

1 reference

inflammatory bowel diseases

5 August 2017

0 references

0 references

author name string

Ardizzone S

series ordinal

1

1 reference

5 August 2017

Bianchi Porro G

series ordinal

2

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

Journal of Internal Medicine

5 August 2017

published in

1 reference

5 August 2017

volume

252

1 reference

5 August 2017

issue

6

1 reference

5 August 2017

page(s)

475-496

1 reference

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Autoimmunity and apoptosis: the Crohn's connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Review article: the genetics of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Stress and immunity in humans: a meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Characterization of spontaneous colitis in cotton-top tamarins (Saguinus oedipus) and its response to sulfasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Appendectomy and the development of ulcerative colitis: results of a metaanalysis of published case-control studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

The indigenous gastrointestinal microflora

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

MMPs in the gut: inflammation hits the matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Blockade of interleukin 6 trans signaling suppresses T-cell resistanceagainst apoptosis in chronic intestinal inflammation: Evidence in Crohn diseaseand experimental colitis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Interleukin-10-deficient mice develop chronic enterocolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Antibodies to interleukin 12 abrogate established experimental colitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

IL-12 and Th1 immune responses in human Peyer's patches

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

The nuclear receptor superfamily: the second decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Evolving treatment strategies for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

TPMT in the treatment of Crohn's disease with azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Treatment of severe Crohn's disease using antimycobacterial triple therapy--approaching a cure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Antisense-oligonucleotide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Vascular complications of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Treatment of corticosteroid-resistant ulcerative colitis with heparin--a report of 16 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Treatment of ulcerative colitis with clonidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Transdermal nicotine for active ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

Crohn's disease: genetic susceptibility, bacteria, and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2002.01067.X

10.1046/J.1365-2796.2002.01067.X

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference